Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease

Table 4 A summary of stem cell-based therapeutic clinical trials in IVD

First author	Phase year	Disease	Treatment	Subject(n) treatment/control	Findings	Ref
Gao, L.R	Phase I/II 2015	CHD	Intracoronary infusion of HUCMSCs	58/58	Myocardial viability/perfusion increase LVEF increase Proven safety	[113]
Qayyum, A.A	Phase II 2019	CHD	Intramyocardial injections of ADSCs	40/20	Low incidence of angina Chest discomfort reduced NYHA classification reduced	[114]
Mathiasen, A.B	Phase II 2019	CHD	Intramyocardial injections of BMSCs	40/20	LVESV reduced Cardiac pump function and myocardial mass improved Myocardial scar tissue reduced Fewer admissions for angina symptoms	[115]
Jaillard, A	Phase I 2020	CAD	Intravenous autologous MSC treatment	20/11	Proven safety and feasibility	[94]

ADSCs Adipose tissue-derived stem cells, BMSCs Bone marrow mesenchymal stem cells, CAD Carotid artery disease, CHD Coronary heart disease, CLI Critical limb ischemia, HUCMSCs Human umbilical cord mesenchymal stem cells, IVD Ischemic vascular disease, LVEF Left ventricular ejection fraction, LVESV Left ventricular end-systolic volume, MSCs Mesenchymal stem cells, NYHA New York Heart Association

ISSN: 1754-1611